Keshava G Reddy, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2200 N Section St, Sullivan, IN 47882 Phone: 812-268-4311 Fax: 812-268-2650 |
Alfred R Talens, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 2200 N Section St, Sullivan, IN 47882 Phone: 812-268-4311 Fax: 812-268-2650 |
Dr. William Eric Heath, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2229 Mary Sherman Dr, Sullivan, IN 47882 Phone: 812-268-3318 Fax: 812-268-4017 |
News Archive
TapImmune Inc. announced that it has signed an exclusive Licensing Option agreement with Mayo Clinic, Rochester, MN, for clinical development of a breast cancer vaccine technology. The option to license this technology can be exercised after Phase I clinical trials under terms agreed between Mayo Clinic and TapImmune.
Scientists at the University of Copenhagen have identified one mechanism that explains how some stem cells choose to become a given cell type: the cells combine specific sets of proteins at precise positions along the DNA. When these particular groups of proteins are combined, the gates are opened so that certain groups of genes can now be used, giving the cells a new identity.
Egalet Corporation, a fully integrated specialty pharmaceutical company focused on discovering, developing, and commercializing innovative pain treatments, today announced that researchers will be presenting scientific data on SPRIX (ketorolac tromethamine) Nasal Spray, Egalet-001, an abuse-deterrent, extended-release, oral morphine product candidate, and Egalet-002, an abuse-deterrent, extended-release, oral oxycodone product in development, at PainWeek 2015 to be held September 8 to 12 in Las Vegas, Nevada.
Despite common assumptions, new research suggests that women are not more likely to be sexually harassed when they are the minority or majority in a work group.
Covidien, a leading global provider of healthcare products, today announced that it received Premarket Approval from the U.S. Food and Drug Administration for the Pipeline Embolization Device, indicated for the endovascular treatment of adults with large or giant wide-necked intracranial aneurysms in the internal carotid artery from the petrous to the superior hypophyseal segments.
› Verified 5 days ago